Analyst Ratings for Madrigal Pharmaceuticals (MDGL)
MDGL Rating Summary
MDGL Price Target Summary
- Highest: $964.00 (Barclays)
- Lowest: $392.00 (Evercore ISI)
- Average: $623.80
* Over Last 12-Mos
Overall Rating:
BUY
Rating Trend:
Avg. $ Target:
$623.80 (+44.1%)
* Over Last 12-Mos
Rating Score: 8.3 / 10
Percentile Rank: 86%
Avg. $ Target:
$623.80 (+44.1%)
* Over Last 12-Mos
Rating Score: 8.3 / 10
Percentile Rank: 86%
| Date | Firm | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 1/28/2026 | Barclays | Eliana Merle | New Coverage | Overweight (N/A) |
964.00 (N/A) |
499.17 (432.83) |
-13.29% | Details |
| 1/6/2026 | Wolfe Research | Andy Chen | Downgrade | Peerperform (Outperform) |
N/A (N/A) |
588.40 (432.83) |
-26.44% | Details |
 |
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
